Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.58B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 3.48M
Average 1.76M
VIR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Vir Biotechnology, Inc.NASDAQ: VIR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$122.71M, compared with -$135.66M a year earlier. Trailing-twelve-month EBITDA was -$438.52M.
Context
- EBITDA amounted to 621.5% of revenue in FY2025, down 64.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$163.24M (+61.7%) for the fiscal year ending Dec 2026, a step up from the +16.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$122.71M-205.5% QoQ
- Last fiscal yearDec 2025
- -$426.09M+16.3% YoY
- LTMMar 2026
- -$438.52M+24.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.5% | +155.1% | +145.5 pp |
| 1 year | +16.3% | +61.7% | +45.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (426.09M) USD
- Year-over-year change
- +16.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (426.09M) | +16.3% |
| FY2024 | 2024-12-31 | (508.91M) | +20.7% |
| FY2023 | 2023-12-31 | (641.64M) | -184.3% |
| FY2022 | 2022-12-31 | 761.06M | +37.0% |
| FY2021 | 2021-12-31 | 555.61M | — |
EBITDA vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.4% is the 4th highest of 10, against a peer median of -30.1%.
- EBITDA amounts to 669.6% of revenue for VIR, versus a peer median of 46.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $160.85M USD | +305.5% | — | 84.0% | |
| LTM Mar 2026 | -$6.26M USD | +84.1% | — | 8.8% | |
| LTM Mar 2026 | -$42.13M USD | -107.6% | — | 7.1% | |
| LTM Mar 2026 | -$46.56M USD | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -€90.14M EUR | -119.6% | — | 57.7% | |
| LTM Mar 2026 | -$179.89M USD | -30.1% | — | — | |
| LTM Jun 2026 | -$302.96M USD | -577.6% | — | 32.2% | |
| LTM Mar 2026 | -$438.52M USD | +24.4% | — | 669.6% | |
| LTM Jun 2026 | -€941.06M EUR | -2167.6% | — | 35.6% | |
| LTM Sep 2026 | -$2.46B USD | +16.4% | — | 97.2% | |
| Peer median (excluding VIR) | — | -30.1% | — | 46.6% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.62B | 86.18M | 74.21M | 68.56M |
| Cost of Revenue | 513.87M | 620.97M | 572.83M | 478.65M | 11.71M |
| Gross Profit | 581.54M | 994.83M | (486.65M) | (404.44M) | 56.85M |
| Gross Margin | 53.1% | 61.6% | -564.7% | -545.0% | 82.9% |
| Research & Development | 448.01M | 474.65M | 579.72M | 506.5M | 432.8M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 92.07M |
| Operating Expenses | 160.79M | 161.76M | 197.66M | 182.73M | 524.87M |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| EBITDA | 555.61M | 761.06M | (641.64M) | (508.91M) | (426.09M) |
| EBITDA Margin | 50.7% | 47.1% | -744.5% | -685.8% | -621.5% |
| Operating Income | 420.75M | 833.07M | (684.31M) | (587.17M) | (468.02M) |
| Operating Margin | 38.4% | 51.6% | -794.0% | -791.3% | -682.7% |
| Interest Income | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 129.05M | (78.79M) | 56.11M | 64.06M | 30.25M |
| Income Before Tax | 549.8M | 754.28M | (628.19M) | (523.11M) | (437.77M) |
| Pre-Tax Margin | 50.2% | 46.7% | -728.9% | -704.9% | -638.6% |
| Income Tax Expense | 21.22M | 238.44M | (13.08M) | (1.15M) | 217K |
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Net Margin | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| EPS (Basic) | 4.07 | 3.89 | (4.59) | (3.83) | (3.16) |
| EPS (Diluted) | 3.96 | 3.83 | (4.59) | (3.83) | (3.16) |
| Weighted Avg Shares | 129.88M | 132.61M | 134.13M | 136.25M | 138.52M |
| Weighted Avg Shares (Diluted) | 133.44M | 134.81M | 134.13M | 136.25M | 138.52M |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.